Health‐related quality of life · People with advanced non‐small cell lung cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · People with advanced non‐small cell lung cancer
Single‐immune checkpoint inhibitors (ICIs) may leads to lower progression‐free survival (PFS) compared with chemotherapy (low certainty).
1 finding from 1 review
Overall response rate (ORR), · People with advanced non‐small cell lung cancer
Single‐immune checkpoint inhibitors (ICIs) may leads to higher overall response rate (ORR) compared with chemotherapy (low certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · People with advanced non‐small cell lung cancer
Single‐immune checkpoint inhibitors (ICIs) may leads to lower adverse Events grade 3‐4 compared with chemotherapy (low certainty).
1 finding from 1 review
QoL · People with advanced non‐small cell lung cancer
Single‐immune checkpoint inhibitors (ICIs) may leads to higher QOL‐C30 GHS/QOL (range 0‐100) ‐ change from baseline to week 15 compared with chemotherapy (low certainty).
1 finding from 1 review
Overall survival (OS) · People with advanced non‐small cell lung cancer
Combined immune checkpoint inhibitors (ICIs) probably leads to lower overall Survival (OS) compared with chemotherapy (moderate certainty).
1 finding from 1 review
Progression‐free survival · People with advanced non‐small cell lung cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall response rate (OSR) · People with advanced non‐small cell lung cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grades 3 and 4 adverse events · People with advanced non‐small cell lung cancer
Combined immune checkpoint inhibitors (ICIs) showed no clear difference in adverse Events grade 3 to 4 compared with chemotherapy (low certainty).
1 finding from 1 review
Symptomatic VTE · ambulatory cancer patients receiving chemotherapy
DOAC showed no clear difference in symptomatic VTE compared with placebo (low certainty).
1 finding from 1 review
Symptomatic PE · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin probably leads to lower symptomatic PE compared with no thromboprophylaxis (moderate certainty).
1 finding from 1 review
Symptomatic DVT · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin leads to lower symptomatic DVT compared with no thromboprophylaxis (high certainty).
1 finding from 1 review
Total VTE · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin leads to lower any VTE compared with no thromboprophylaxis (high certainty).
1 finding from 1 review
1‐year overall mortality · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin showed no clear difference in 1‐year overall mortality compared with no thromboprophylaxis (low certainty).
1 finding from 1 review
Clinically relevant bleeding · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin probably leads to higher clinically relevant bleeding compared with no thromboprophylaxis (moderate certainty).
1 finding from 1 review
Symptomatic VTE · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin showed no clear difference in symptomatic VTE compared with with active control (1) (low certainty).
3 findings from 1 review
RR 2.89 [0.12, 66.75]
1 study · 51 participants
Low
RR 0.51 [0.22, 1.17]
2 studies · 781 participants
Moderate
RR 0.33 [0.14, 0.83]
1 study · 439 participants
High
Major bleeding · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
3 findings from 1 review
Symptomatic PE · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin showed no clear difference in symptomatic PE compared with with active control (1); GRADE not reported.
3 findings from 1 review
Symptomatic DVT · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
3 findings from 1 review
Total VTE · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin showed no clear difference in any VTE compared with with active control (1); GRADE not reported.
3 findings from 1 review
RR 4.81 [0.24, 95.58]
Studies not reported
GRADE not reported
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found